Mr. Andrew Bruce is the international lead on HTA and Payment Policy for AMGEN. He is also responsible for EU Biosimilars policy. He reports directly to Herb Riband, Vice-President, Global Value, Access and Policy. He is currently an active member of EFPIA's HTA taskforce, the technical working group of the CEE Taskforce, and a stakeholder advisory group for EUnetHTA engagement.

Prior to joining Amgen in September 2012, Mr. Bruce was the Director, Health Policy and Research at Medicines Australia where he was actively involved in discussions and negotiations on HTA and reimbursement policy with the Australian government, the Department of Health and Ageing and its principle HTA body, the Pharmaceutical Benefits Advisory Committee (PBAC).

In this role, Mr. Bruce was a key member of the negotiation team on the 4 year industry/government framework agreement (Memorandum of Understanding) on reforms to the Australian pricing and reimbursement system. Included within this agreement were a number of initiatives to improve patient access to medicines, including the introduction of parallel processing of regulatory and reimbursement applications; and Coverage with Evidence Development or managed entry scheme provision designed to better manage some forms of uncertainty in submissions to the PBAC for public reimbursement.

Mr. Bruce served as a member of the Access to Medicines Working Group, a key industry/government consultation body whose members were appointed by the Australian Minister for Health and Ageing. In this capacity he worked with government officials on a number of central reimbursement and HTA related policy issues including processes and frameworks for assessing co-dependent technologies, including so-called personalized medicines; tools for managing uncertainty in HTA including CED; efficient markets for pricing off-patents medicines; impacts of comparator selection policies; and the reimbursement of biosimilars.

Mr. Bruce was the industry's representative on the two key HTA appraisal committees, the Economic Sub-Committee and the Drug Utilisation Sub-committee of the PBAC. At various stages he was also both an industry advisor to and a full member of the Pharmaceutical Benefits Pricing Authority. In addition, Mr. Bruce was a member of the PBAC Guidelines Working Group, which oversees the incorporation of methodological or evidentiary requirements into Guidelines for submission to the PBAC

Mr. Bruce has also served industry as the Co-Chair of the Medicines Australia Access Strategic Committee, which provided the Medicines Australia Chief Executive Officer and the Board of Directors with strategic counsel and policy advice on regulatory and reimbursement policy. He was also Co-Chair of MA's Health Economics Working Group, which undertook methodological and technical work on reimbursement and pricing matters.

Mr Bruce was educated at the University of Sydney.